|
|
Article: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results.(Financial report)
- Article from:
- Clinical Trials Week
- Article date:
- November 16, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BioSpecifics Technologies Corp. (NASDAQ:BSTC), a biopharmaceutical company developing first-in-class collagenase-based products, announced its financial results for the third quarter ended September 30, 2009 (see also Enzyme Research).
"We were extremely happy that, in September of this year, the FDA's Arthritis Advisory Committee unanimously recommended, by a vote of 12-0, the approval of XIAFLEX™ for the treatment of Dupuytren's disease, and we are eagerly awaiting a response on the Biologics License Application that was submitted by our partner, Auxilium," stated Thomas L. Wegman, President of BioSpecifics. "We also look forward to the Phase IIb results ...
Related newspaper, magazine, and journal articles:
|